C R Dass

Summary

Affiliation: St Vincent's Hospital
Country: Australia

Publications

  1. ncbi Selective gene delivery for cancer therapy using cationic liposomes: in vivo proof of applicability
    Crispin R Dass
    Department of Orthopaedics, University of Melbourne, St Vincent s Hospital Melbourne, P O Box 2900, Fitzroy 3065, Australia
    J Control Release 113:155-63. 2006
  2. ncbi Downregulation of uPAR confirms link in growth and metastasis of osteosarcoma
    Crispin R Dass
    Department of Orthopaedics, The University of Melbourne, St Vincent s Hospital Melbourne, P O Box 2900, 3065 Fitzroy, Vic, Australia
    Clin Exp Metastasis 22:643-52. 2005
  3. ncbi Biocompatible chitosan-DNAzyme nanoparticle exhibits enhanced biological activity
    Crispin R Dass
    Department of Orthopaedics, St Vincent s Hospital, Vic, Australia
    J Microencapsul 25:421-5. 2008
  4. ncbi Carrier-mediated delivery of peptidic drugs for cancer therapy
    Crispin R Dass
    Department of Orthopaedics, St Vincent s Hospital Melbourne, St Vincent s Hospital Melbourne, P O Box 2900, Fitzroy 3065, Melbourne, Vic, Australia
    Peptides 27:3020-8. 2006
  5. ncbi The use of chitosan formulations in cancer therapy
    Crispin R Dass
    Departments of Orthopaedics and Surgery, University of Melbourne, St Vincent s Hospital, Melbourne, Australia
    J Microencapsul 25:275-9. 2008
  6. ncbi Chitosan-mediated orally delivered nucleic acids: a gutful of gene therapy
    Crispin R Dass
    Departments of Orthopaedics and Surgery, University of Melbourne, St Vincent s Hospital Melbourne, Fitzroy, Australia
    J Drug Target 16:257-61. 2008
  7. ncbi Biophysical delivery of peptides: applicability for cancer therapy
    Crispin R Dass
    Department of Orthopaedics, University of Melbourne, St Vincent s Hospital Melbourne, P O Box 2900, Fitzroy 3065, Australia
    Peptides 27:3479-88. 2006
  8. ncbi Human xenograft osteosarcoma models with spontaneous metastasis in mice: clinical relevance and applicability for drug testing
    Crispin R Dass
    Department of Orthopaedics, University of Melbourne, St Vincent s Hospital, Fitzroy, VIC 3065, Australia
    J Cancer Res Clin Oncol 133:193-8. 2007
  9. ncbi A novel orthotopic murine model provides insights into cellular and molecular characteristics contributing to human osteosarcoma
    Crispin R Dass
    Department of Orthopaedics, The University of Melbourne St Vincent s Hospital, P O Box 2900, Melbourne, Fitzroy, 3065 VIC, Australia
    Clin Exp Metastasis 23:367-80. 2006
  10. ncbi Chitosan microparticles encapsulating PEDF plasmid demonstrate efficacy in an orthotopic metastatic model of osteosarcoma
    Crispin R Dass
    Department of Orthopaedics, University of Melbourne, St Vincent s Health, P O Box 2900, Fitzroy, 3065 Melbourne, Australia
    Biomaterials 28:3026-33. 2007

Collaborators

Detail Information

Publications83

  1. ncbi Selective gene delivery for cancer therapy using cationic liposomes: in vivo proof of applicability
    Crispin R Dass
    Department of Orthopaedics, University of Melbourne, St Vincent s Hospital Melbourne, P O Box 2900, Fitzroy 3065, Australia
    J Control Release 113:155-63. 2006
    ..This review looks at the state of play in this rapidly growing field...
  2. ncbi Downregulation of uPAR confirms link in growth and metastasis of osteosarcoma
    Crispin R Dass
    Department of Orthopaedics, The University of Melbourne, St Vincent s Hospital Melbourne, P O Box 2900, 3065 Fitzroy, Vic, Australia
    Clin Exp Metastasis 22:643-52. 2005
    ..05), and total inhibition of pulmonary metastases were observed in mice injected with the more potent of the antisense clones. This study proves seminally the usefulness of uPAR antisense in curbing the growth and spread of osteosarcoma...
  3. ncbi Biocompatible chitosan-DNAzyme nanoparticle exhibits enhanced biological activity
    Crispin R Dass
    Department of Orthopaedics, St Vincent s Hospital, Vic, Australia
    J Microencapsul 25:421-5. 2008
    ..The formulation was stable in serum for a week and at room temperature for a month. Clinically, knockdown of c-jun gene expression with chitosan nanobiotechnology may improve treatment outcome for tumours growing in bone...
  4. ncbi Carrier-mediated delivery of peptidic drugs for cancer therapy
    Crispin R Dass
    Department of Orthopaedics, St Vincent s Hospital Melbourne, St Vincent s Hospital Melbourne, P O Box 2900, Fitzroy 3065, Melbourne, Vic, Australia
    Peptides 27:3020-8. 2006
    ..A brief look at the types of peptidic drugs currently in use clinically, and a brief discourse on several novel ideas for better protein delivery systems for cancer therapy is included...
  5. ncbi The use of chitosan formulations in cancer therapy
    Crispin R Dass
    Departments of Orthopaedics and Surgery, University of Melbourne, St Vincent s Hospital, Melbourne, Australia
    J Microencapsul 25:275-9. 2008
    ..The future of this promising technology lies in the evolution of new ideas for enhanced nucleic acid drug pharmacokinetics and, consequently, pharmacodynamics for cancer patients...
  6. ncbi Chitosan-mediated orally delivered nucleic acids: a gutful of gene therapy
    Crispin R Dass
    Departments of Orthopaedics and Surgery, University of Melbourne, St Vincent s Hospital Melbourne, Fitzroy, Australia
    J Drug Target 16:257-61. 2008
    ....
  7. ncbi Biophysical delivery of peptides: applicability for cancer therapy
    Crispin R Dass
    Department of Orthopaedics, University of Melbourne, St Vincent s Hospital Melbourne, P O Box 2900, Fitzroy 3065, Australia
    Peptides 27:3479-88. 2006
    ..This review discusses these methods in turn, and examines ways by which these can be enhanced for peptide delivery to tumors...
  8. ncbi Human xenograft osteosarcoma models with spontaneous metastasis in mice: clinical relevance and applicability for drug testing
    Crispin R Dass
    Department of Orthopaedics, University of Melbourne, St Vincent s Hospital, Fitzroy, VIC 3065, Australia
    J Cancer Res Clin Oncol 133:193-8. 2007
    ..This review tackles this conundrum and lists the variety of models (that use human osteosarcoma cells) available and the types of studies performed with these...
  9. ncbi A novel orthotopic murine model provides insights into cellular and molecular characteristics contributing to human osteosarcoma
    Crispin R Dass
    Department of Orthopaedics, The University of Melbourne St Vincent s Hospital, P O Box 2900, Melbourne, Fitzroy, 3065 VIC, Australia
    Clin Exp Metastasis 23:367-80. 2006
    ..The newly established SaOS-2 model should allow the testing of candidate anti-osteosarcoma agents as well as dissection of more intricate mechanisms involved in human osteosarcoma...
  10. ncbi Chitosan microparticles encapsulating PEDF plasmid demonstrate efficacy in an orthotopic metastatic model of osteosarcoma
    Crispin R Dass
    Department of Orthopaedics, University of Melbourne, St Vincent s Health, P O Box 2900, Fitzroy, 3065 Melbourne, Australia
    Biomaterials 28:3026-33. 2007
    ..Thus, this new mode of localised gene delivery may hold promise for molecular therapy of osteosarcoma...
  11. ncbi Gene therapy for osteosarcoma: steps towards clinical studies
    Crispin R Dass
    Department of Orthopaedics, University of Melbourne, St Vincent s Hospital Melbourne, Australia
    J Pharm Pharmacol 60:405-13. 2008
    ..Drawing from the experiences of gene therapy against other cancers, studies for which have already reached the clinical phase, the review discusses potential pitfalls and solutions to enhance gene therapy for osteosarcoma...
  12. ncbi Pigment epithelium-derived factor (PEDF): drug developmental challenges ahead for a budding anti-angiogenic
    C R Dass
    Department of Orthopaedics, St Vincent s Hospital, Melbourne, Australia
    Pharmazie 63:4-6. 2008
    ..The next obvious challenge is to find ways to deliver this molecule in vivo with enhanced pharmacodynamics and reduced toxicity. Several methods to achieve this are proposed...
  13. ncbi GFP expression alters osteosarcoma cell biology
    Crispin R Dass
    Department of Orthopaedics, University of Melbourne St Vincent s Hospital Melbourne, Fitzroy, Victoria, Australia
    DNA Cell Biol 26:599-601. 2007
    ..The use of GFP for cell tracking in osteosarcoma animal models should therefore be used with caution...
  14. ncbi DNAzyme technology and cancer therapy: cleave and let die
    Crispin R Dass
    Department of Orthopaedics, St Vincent s Hospital Melbourne, Fitzroy, VIC 3065, Australia
    Mol Cancer Ther 7:243-51. 2008
    ..This review documents the rise of DNAzymes in the fight against cancer and serves as a forecast for this promising biotechnology in this context...
  15. ncbi Angiogenesis inhibitors and the need for anti-angiogenic therapeutics
    C R Dass
    Department of Orthopaedics, University of Melbourne, St Vincent s Health, P O Box 2900, Fitzroy, 3065, Melbourne, Australia
    J Dent Res 86:927-36. 2007
    ..This review looks at the common angiogenic inhibitors (angiostatin, endostatin, maspin, pigment epithelium-derived factor, bevacizumab and other monoclonal antibodies, and zoledronic acid) and their current status in clinical trials...
  16. ncbi C-jun: pharmaceutical target for DNAzyme therapy of multiple pathologies
    C R Dass
    Department of Orthopaedics, St Vincent s Hospital, Peter MacCallum Cancer Centre, Melbourne, Australia
    Pharmazie 63:411-4. 2008
    ..Importantly, downregulation of c-jun is noted to cause apoptotic death of cancer cells. These studies collectively demonstrate the potential of this DNAzyme as a lead candidate for DNAzyme therapeutics...
  17. ncbi Zoledronic acid inhibits osteosarcoma growth in an orthotopic model
    Crispin R Dass
    Department of Orthopaedics, St Vincent s Hospital Melbourne, P O Box 2900, Fitzroy 3065, Melbourne, Australia
    Mol Cancer Ther 6:3263-70. 2007
    ....
  18. ncbi PEDF as an emerging therapeutic candidate for osteosarcoma
    Crispin R Dass
    Department of Orthopaedics and Surgery, University of Melbourne, St Vincent s Hospital, Melbourne, Australia
    Curr Cancer Drug Targets 8:683-90. 2008
    ..Current efforts are devoted to develop drug delivery systems, such as controlled release nanoparticles, that can be used to progress this potential drug candidate closer towards clinical trials for OS...
  19. ncbi PEDF-derived synthetic peptides exhibit antitumor activity in an orthotopic model of human osteosarcoma
    Eugene T H Ek
    Department of Orthopaedics, University of Melbourne, St Vincent s Hospital, Melbourne, P O Box 2900, Fitzroy, 3065, Melbourne, Vic, Australia
    J Orthop Res 25:1671-80. 2007
    ..Furthermore, this raises the possibility of developing short PEDF fragments as lead compounds for the treatment of osteosarcoma...
  20. ncbi Pigment epithelium-derived factor overexpression inhibits orthotopic osteosarcoma growth, angiogenesis and metastasis
    E T H Ek
    Department of Orthopaedics, University of Melbourne, St Vincent s Hospital, Melbourne, Victoria, Australia
    Cancer Gene Ther 14:616-26. 2007
    ..05). Therefore, together these results suggest that PEDF may be a new and promising approach for the treatment of osteosarcoma...
  21. ncbi The pathophysiological role of PEDF in bone diseases
    M L Broadhead
    Department of Orthopaedics and University of Melbourne Department of Surgery, St Vincent s Hospital, Vic, Australia
    Curr Mol Med 10:296-301. 2010
    ..Surprisingly, the role of PEDF has not been evaluated more widely in bone disorders, so the challenge ahead lies in a more diverse evaluation of PEDF in various osteologic pathologies including osteoarthritis and fracture healing...
  22. ncbi A chitosan hydrogel delivery system for osteosarcoma gene therapy with pigment epithelium-derived factor combined with chemotherapy
    Hang T Ta
    Department of Chemical and Biomolecular Engineering, University of Melbourne, Victoria 3010, Australia
    Biomaterials 30:4815-23. 2009
    ..The results obtained from this study demonstrate the potential application of a biodegradable hydrogel technology as an anti-cancer drug delivery system for successful chemo-gene therapy...
  23. ncbi Systemically administered PEDF against primary and secondary tumours in a clinically relevant osteosarcoma model
    M L Broadhead
    Department of Orthopaedics, St Vincent s Hospital Melbourne, Level 3, Daly Wing, 35 Victoria Pde, Fitzroy, VIC 3065, Australia
    Br J Cancer 105:1503-11. 2011
    ..Animal studies have demonstrated the biological effects of PEDF on osteosarcoma; however, these results are difficult to extrapolate for human use due to the chosen study design and drug delivery methods...
  24. ncbi The performance of doxorubicin encapsulated in chitosan-dextran sulphate microparticles in an osteosarcoma model
    Mei L Tan
    Department of Orthopaedics, St Vincent s Hospital Melbourne, Fitzroy, VIC 3065, Australia
    Biomaterials 31:541-51. 2010
    ..Thus, DMP may prove to be a useful DDS platform clinically provided further studies are performed to rigorously validate this technology...
  25. ncbi Downregulation of c-jun results in apoptosis-mediated anti-osteosarcoma activity in an orthotopic model
    Crispin R Dass
    Department of Orthopaedics and University of Melbourne Department of Surgery, St Vincent s Hospital, Victoria, Australia
    Cancer Biol Ther 7:1033-6. 2008
    ..The 60 nm DDAB:DOPE liposome was formulated using ethanol injection/extrusion. Clinically, downregulation of c-jun may proffer an improved treatment outcome for these tumours originating in bone...
  26. ncbi Inhibition of orthotopic osteosarcoma growth and metastasis by multitargeted antitumor activities of pigment epithelium-derived factor
    Eugene T H Ek
    Department of Orthopaedics, University of Melbourne, St Vincent s Hospital, P O Box 2900, Fitzroy, Melbourne, 3065 VIC, Australia
    Clin Exp Metastasis 24:93-106. 2007
    ..These results suggest that PEDF is emerging as an attractive and clinically appealing drug candidate for the treatment of osteosarcoma...
  27. ncbi c-Jun Is critical for the progression of osteosarcoma: proof in an orthotopic spontaneously metastasizing model
    Crispin R Dass
    Department of Orthopaedics, St Vincent s Hospital, Fitzroy, Melbourne, Victoria 3065, Australia
    Mol Cancer Res 6:1289-92. 2008
    ..Clinically, knockdown of c-Jun with DNAzymes may proffer an improved treatment outcome for these tumors originating in bone...
  28. ncbi A chitosan-dipotassium orthophosphate hydrogel for the delivery of Doxorubicin in the treatment of osteosarcoma
    Hang T Ta
    Department of Chemical and Biomolecular Engineering, University of Melbourne, VIC 3010, Australia
    Biomaterials 30:3605-13. 2009
    ..The results obtained from this study demonstrate the potential application of a biodegradable hydrogel technology as an anti-cancer drug delivery system for successful chemotherapy...
  29. ncbi Development of chondrosarcoma animal models for assessment of adjuvant therapy
    J C M Clark
    Department of Orthopaedics, University of Melbourne Department of Surgery, St Vincent s Health, Melbourne, Australia
    ANZ J Surg 79:327-36. 2009
    ..More clinically relevant models of human chondrosarcoma progression are required either through transgenic mice or orthotopic human xenograft models...
  30. ncbi Recent developments in liposomes, microparticles and nanoparticles for protein and peptide drug delivery
    Mei Lin Tan
    Department of Orthopedics, University of Melbourne, St Vincent s Hospital Melbourne, Fitzroy, Australia
    Peptides 31:184-93. 2010
    ..This review discusses the recent developments in the fields of liposome, microparticle and nanoparticle pertinent to protein and peptide delivery covering those systems tested and/or validated in vivo...
  31. ncbi PEDF: a potential molecular therapeutic target with multiple anti-cancer activities
    Eugene T H Ek
    Department of Orthopaedics, University of Melbourne St. Vincent's Hospital, Melbourne, PO Box 2900, Fitzroy, Melbourne, Australia
    Trends Mol Med 12:497-502. 2006
    ..We also discuss the prospects for PEDF therapy and the need for a closer evaluation of issues such as delivery, stability and potential toxicity...
  32. ncbi Anti-chondrosarcoma effects of PEDF mediated via molecules important to apoptosis, cell cycling, adhesion and invasion
    Mei Lin Tan
    Department of Orthopaedics, St Vincent s Hospital Melbourne, Vic, Australia
    Biochem Biophys Res Commun 398:613-8. 2010
    ..These findings seminally indicate that PEDF may have potential as an anti-cancer agent against chondrosarcoma...
  33. ncbi Lipoplex-mediated delivery of nucleic acids: factors affecting in vivo transfection
    Crispin R Dass
    GeneType Research Labs, 60 70 Hanover Street, 3065 Fitzroy, Australia
    J Mol Med (Berl) 82:579-91. 2004
    ..More research is needed to understand the basic biology behind lipofection, first at the cellular level, then at the multicellular (whole organism) level...
  34. ncbi Tumour angiogenesis, vascular biology and enhanced drug delivery
    Crispin R Dass
    GeneType Research Labs, Fitzroy, Australia
    J Drug Target 12:245-55. 2004
    ..This review examines, from various viewpoints, the area of tumour angiogenesis and vascularisation, currently one of the most fertile and active fields of cancer research...
  35. ncbi uPAR mediates anticancer activity of PEDF
    Crispin R Dass
    Department of Orthopaedics, St Vincent s Hospital Melbourne, University of Melbourne, Australia
    Cancer Biol Ther 7:1262-70. 2008
    ....
  36. ncbi Dz13, a c-jun DNAzyme, is a potent inducer of caspase-2 activation
    Crispin R Dass
    Department of Orthopaedics, St Vincent s Hospital Melbourne, Fitzroy, Vic, Australia
    Oligonucleotides 20:137-46. 2010
    ..These findings provide hope that Dz13, and other agents that evoke activation of caspase-2, may be therapeutic clinically...
  37. ncbi A nanoparticulate system that enhances the efficacy of the tumoricide Dz13 when administered proximal to the lesion site
    Mei Lin Tan
    Department of Orthopaedics, St Vincent s Hospital Melbourne, Vic, Australia
    J Control Release 144:196-202. 2010
    ..However, no toxicity against other bone-dwelling cells was observed with the formulation, and no side-effects were noted in vivo in lymphatic and reticuloendothelial tissues proximal and distal to the administration site...
  38. ncbi Oligonucleotide delivery to tumours using macromolecular carriers
    Crispin R Dass
    RareCellect, Genetic Technologies Research Laboratories, 60 66 Hanover Street, Fitzroy 3065, Melbourne, Victoria 3073, Australia
    Biotechnol Appl Biochem 40:113-22. 2004
    ..It also proposes how microparticles can be utilized for delivery of ONs to solid tumours. Prospects for improved ON delivery using these carriers and ways to achieve this are discussed...
  39. ncbi In vitro and in vivo biological activity of PEDF against a range of tumors
    Matthew L Broadhead
    University of Melbourne, St Vincent s Hospital, Department of Orthopaedics and Surgery, L3, Daly Wing, 35 Victoria Pde, Fitzroy 3065, Vic, Australia
    Expert Opin Ther Targets 13:1429-38. 2009
    ..These direct and indirect effects of PEDF have been examined in vitro and in vivo for a range of malignancies...
  40. ncbi Pigment epithelium-derived factor: a multimodal tumor inhibitor
    Eugene T H Ek
    Department of Orthopaedics, St. Vincent's Hospital, P.O. Box 2900, Fitzroy, 3065 Melbourne, Australia
    Mol Cancer Ther 5:1641-6. 2006
    ..Although there is a substantial amount of work carried out at the preclinical stage with this protein, more groundwork has to be done before PEDF is tested against cancer in clinical trials...
  41. ncbi Current and future treatments of bone metastases
    J C M Clark
    University of Melbourne, St Vincent s Hospital, St Vincent s Health, Department of Surgery and Orthopaedics, Level 3 Daly Wing, 41 Victoria Parade, Fitzroy, Vic, 3053, Australia
    Expert Opin Emerg Drugs 13:609-27. 2008
    ..Direct inhibition of metastasis progression and osteolysis with less reliance on cytotoxic agents and invasive therapy should result in improved metastatic control, longer survival and less overall morbidity...
  42. ncbi Non-viral methods for gene transfer towards osteosarcoma therapy
    Crispin R Dass
    Department of Orthopaedics, St Vincent s Hospital Melbourne, University of Melbourne, Fitzroy, Australia
    J Drug Target 15:184-9. 2007
    ..The field is still in its infancy as far as osteosarcoma is concerned and much more needs to be done to test its true potential as a feasible therapeutic modality...
  43. ncbi Therapeutic targeting of osteoclast function and pathways
    Matthew L Broadhead
    St Vincent s Hospital, Department of Orthopaedics and University of Melbourne, Department of Surgery, L3, Daly Wing, 35 Victoria Parade, Fitzroy 3065, Vic, Australia
    Expert Opin Ther Targets 15:169-81. 2011
    ..Targeting of osteoclast control mechanisms offers the potential of combining 'molecular imaging' with therapeutic intervention and longitudinal monitoring of disease processes...
  44. ncbi Sequence-related off-target effect of Dz13 against human tumor cells and safety in adult and fetal mice following systemic administration
    Crispin R Dass
    Department of Orthopaedics, St Vincent s Hospital Melbourne, Fitzroy, Victoria, Australia
    Oligonucleotides 20:51-60. 2010
    ..It was also void of adverse effects to the physiological processes of angiogenesis and apoptosis. Collectively, the data support the safety of Dz13 and its activity attributed to off-target effects...
  45. ncbi PEDF regulates osteoclasts via osteoprotegerin and RANKL
    Toru Akiyama
    Departments of Orthopaedics and Surgery, University of Melbourne, St Vincent s Health, Melbourne, Australia
    Biochem Biophys Res Commun 391:789-94. 2010
    ..These results suggest that PEDF inhibits OCL function via regulating OPG expression, and thereby contributes to the maintenance of bone homeostasis...
  46. ncbi Drug delivery in cancer using liposomes
    Crispin R Dass
    Department of Orthopaedics, St Vincent ps Hospital Melbourne, Fitzroy, Vic, Australia
    Methods Mol Biol 437:177-82. 2008
    ..This chapter describes the more rigorous and easy methods used for liposome manufacture, with references, to aid the reader in preparing these formulations in-house...
  47. ncbi Cancer, chitosan nanoparticles and catalytic nucleic acids
    Mei Lin Tan
    Department of Orthopaedics, University of Melbourne, St Vincent s Hospital Melbourne, P O Box 2900, Fitzroy 3065, Australia
    J Pharm Pharmacol 61:3-12. 2009
    ..The aim of this review was to examine gene therapy involving DNAzyme and siRNA encapsulation into chitosan nanoparticles, discussing the current and future status of this drug delivery system in enhancing drug delivery and cancer therapy...
  48. ncbi Osteosarcoma treatment: state of the art
    Hang T Ta
    Department of Chemical and Biomolecular Engineering, University of Melbourne, Melbourne, Vic, 3010, Australia
    Cancer Metastasis Rev 28:247-63. 2009
    ..This article reviews the biology and the state of the art management of OS. New experimental drugs and potential therapies targeting molecular pathways of OS are also discussed...
  49. ncbi Cancer cell apoptotic pathways mediated by PEDF: prospects for therapy
    Matthew L Broadhead
    Department of Orthopaedics and University of Melbourne Department of Surgery, St Vincent s Hospital, Vic, Australia
    Trends Mol Med 15:461-7. 2009
    ....
  50. ncbi Cancer angiogenesis: targeting the heel of Achilles
    Crispin R Dass
    Department of Orthopaedics and Surgery, University of Melbourne, St Vincent s Hospital Melbourne, Melbourne, Australia
    J Drug Target 16:449-54. 2008
    ..This review looks at the current state of play in the area of cancer angiogenesis, and development of therapies to target it...
  51. ncbi Involvement of c-jun in human liposarcoma growth: supporting data from clinical immunohistochemistry and DNAzyme efficacy
    Crispin R Dass
    Department of Orthopaedics and University of Melbourne Department of Surgery, St Vincent s Hospital, Fitzroy, Victoria, Australia
    Cancer Biol Ther 7:1297-301. 2008
    ..Clinically, downregulation of c-jun may proffer an improved treatment outcome for liposarcoma. The new model for LS described here will enable better testing of agents with therapeutic potential against LS...
  52. ncbi A review of clinical and molecular prognostic factors in osteosarcoma
    Jonathan C M Clark
    Department of Orthopaedics, University of Melbourne, St Vincent s Hospital, P O Box 2900, Fitzroy, Melbourne, VIC 3065, Australia
    J Cancer Res Clin Oncol 134:281-97. 2008
    ....
  53. ncbi Commonly used mouse models of osteosarcoma
    Eugene T H Ek
    Department of Orthopaedics, University of Melbourne, St. Vincent's Hospital, P.O. Box 2900, Fitzroy, Vic, Melbourne 3065, Australia
    Crit Rev Oncol Hematol 60:1-8. 2006
    ..Given that osteosarcoma is a disease that affects young people and better disease management strategies are essential, development of a robust human osteosarcoma model is long overdue...
  54. ncbi RECK--a newly discovered inhibitor of metastasis with prognostic significance in multiple forms of cancer
    Jonathan C M Clark
    Department of Orthopaedics, St Vincent s Hospital, University of Melbourne, Melbourne, Australia
    Cancer Metastasis Rev 26:675-83. 2007
    ..Although further research is required, RECK is a promising prognostic marker and potential therapeutic agent in multiple cancers...
  55. ncbi Injectable chitosan hydrogels for localised cancer therapy
    Hang Thu Ta
    Department of Chemical and Biomolecular Engineering, The University of Melbourne, Australia, Vic
    J Control Release 126:205-16. 2008
    ....
  56. ncbi Dz13 induces a cytotoxic stress response with upregulation of E2F1 in tumor cells metastasizing to or from bone
    Crispin R Dass
    Department of Orthopaedics, St Vincent s Hospital Melbourne, Fitzroy, Australia
    Oligonucleotides 20:79-91. 2010
    ..These results provide an off-target mechanism for Dz13 function, but this may be useful therapeutically against tumors...
  57. ncbi RANK-Fc inhibits malignancy via inhibiting ERK activation and evoking caspase-3-mediated anoikis in human osteosarcoma cells
    Toru Akiyama
    Departments of Orthopaedics and Surgery, St Vincent s Health, University of Melbourne, Fitzroy, Melbourne, VIC 3065, Australia
    Clin Exp Metastasis 27:207-15. 2010
    ..In vivo, activity of the RANK-Fc against OS cell migration and invasion was confirmed in a model strictly monitoring metastasis. Thus, RANK-Fc, given its ability to directly reduce OS aggression, is a potential drug candidate...
  58. ncbi Microarray: an instrument for cancer surgeons of the future?
    Matthew L Broadhead
    Department of Orthopaedics University of Melbourne, St Vincent s Hospital, Vic, Australia
    ANZ J Surg 80:531-6. 2010
    ..This review outlines the science of microarray and draws on clinical examples, including osteosarcoma, breast, prostate and pancreatic carcinomas, to highlight the potential of microarray as a technique of surgical importance...
  59. ncbi DNAzyme delivery systems: getting past first base
    Mei Lin Tan
    University of Melbourne, Melbourne, Australia
    Expert Opin Drug Deliv 6:127-38. 2009
    ..The challenge ahead for DNAzymes to be considered genuine drug candidates alongside siRNA and antisense simply lies in the better implementation of DDSs...
  60. ncbi Chitosan-dibasic orthophosphate hydrogel: a potential drug delivery system
    Hang T Ta
    Department of Chemical and Biomolecular Engineering, University of Melbourne, VIC 3010, Australia
    Int J Pharm 371:134-41. 2009
    ..These results indicate the potential of Chi/DHO hydrogels as delivery systems for different therapeutic agents with controlled release kinetics...
  61. ncbi The urokinase plasminogen activator receptor as a gene therapy target for cancer
    Vinochani Pillay
    Department of Orthopaedics, St Vincent s Hospital Melbourne, PO Box 2900, Fitzroy 3065, Melbourne, Vic, Australia
    Trends Biotechnol 25:33-9. 2007
    ..Preclinical studies are advancing towards the translational phase, provided that established orthotopic tumours, which mimic clinical progression and presentation, are treated using clinically acceptable modes of nucleic acid delivery...
  62. ncbi Review: doxorubicin delivery systems based on chitosan for cancer therapy
    Mei Lin Tan
    Department of Orthopaedics and Surgery, University of Melbourne, St Vincent s Hospital Melbourne, Melbourne, Australia
    J Pharm Pharmacol 61:131-42. 2009
    ....
  63. ncbi c-Jun knockdown sensitizes osteosarcoma to doxorubicin
    Crispin R Dass
    Department of Orthopaedics, St Vincent s Hospital Melbourne, P O Box 2900, Fitzroy, Victoria 3065, Australia
    Mol Cancer Ther 7:1909-12. 2008
    ..c-Jun down-regulation-mediated tumor inhibition also led to concomitant decreased osteolysis. Clinically, knockdown of c-Jun with chitosan nanobiotechnology may proffer an improved treatment outcome for osteosarcoma...
  64. ncbi Osteosarcoma: Conventional treatment vs. gene therapy
    Mei Lin Tan
    Department of Orthopaedics, University of Melbourne, St Vincent s Hospital Melbourne, Melbourne, Australia
    Cancer Biol Ther 8:106-17. 2009
    ....
  65. ncbi Deoxyribozymes: cleaving a path to clinical trials
    Crispin R Dass
    GeneType Research Laboratories, 60 Hanover Street, Fitzroy 3065, Victoria, Australia
    Trends Pharmacol Sci 25:395-7. 2004
    ..Rigorous testing in preclinical studies is now required before this relatively new entity enters Phase I clinical trials...
  66. ncbi Novel therapeutic strategy for osteosarcoma targeting osteoclast differentiation, bone-resorbing activity, and apoptosis pathway
    Toru Akiyama
    Department of Orthopaedics Surgery, University of Melbourne, St Vincent s Health, Fitzroy 3065, Melbourne, Victoria, Australia
    Mol Cancer Ther 7:3461-9. 2008
    ..This review article will attempt to discuss these issues in term...
  67. ncbi Preclinical anticancer activity of DNA-based cleavage molecules
    Crispin R Dass
    Department of Orthopaedics, St Vincents Hospital, 35 Victoria Parade, Fitzroy, 3065, Australia
    Drug Dev Ind Pharm 32:1-5. 2006
    ..While a significant amount of work has gone into chemically stabilizing the molecule, delivery is one area that needs particular attention...
  68. ncbi Bim-targeted cancer therapy: a link between drug action and underlying molecular changes
    Toru Akiyama
    Department of Orthopaedics, University of Melbourne, and St Vincent s Hospital Melbourne, L3 Daly Wing, 35 Victoria Pde, Fitzroy, Melbourne, VIC 3065 Australia
    Mol Cancer Ther 8:3173-80. 2009
    ..Thus, Bim-targeting therapies may provide more effective and unique tumor management modalities in future. This review article discusses all these issues...
  69. ncbi Modified microplex vector enhances transfection of cells in culture while maintaining tumour-selective gene delivery in-vivo
    Crispin R Dass
    Charles Sturt University, Box 588, Wagga Wagga, NSW 2678, Australia
    J Pharm Pharmacol 55:19-25. 2003
    ....
  70. ncbi In-vitro and in-vivo assays for angiogenesis-modulating drug discovery and development
    Michelle W Phung
    Cancer Biology and Lead Discovery, Cryptome Pharmaceuticals Pty. Ltd, Level 1, Baker Heart Research Institute, Commercial Road, Melbourne 3004, Australia
    J Pharm Pharmacol 58:153-60. 2006
    ..More clinically relevant models are needed as anti-angiogenesis drug discovery and drug development companies fast track their lead molecules from preclinical investigations to phase I clinical trials...
  71. ncbi Inhibition of human breast carcinoma proliferation, migration, chemoinvasion and solid tumour growth by DNAzymes targeting the zinc finger transcription factor EGR-1
    Ainslie Mitchell
    Department of Haematology, Centre for Vascular Research, The University of New South Wales, Sydney, NSW 2052, Australia
    Nucleic Acids Res 32:3065-9. 2004
    ..Thus, DNAzymes targeting specific genes can inhibit multiple key tumorigenic processes in vitro and in vivo and may serve as useful anti-cancer agents...
  72. ncbi Liposomes containing cationic dimethyl dioctadecyl ammonium bromide: formulation, quality control, and lipofection efficiency
    Crispin R Dass
    Charles Sturt University, Wagga Wagga, Australia
    Drug Deliv 9:11-8. 2002
    ....
  73. ncbi Effect of deoxyribozymes targeting c-Jun on solid tumor growth and angiogenesis in rodents
    Guishui Zhang
    Centre for Vascular Research, The University of New South Wales and Department of Haematology, The Prince of Wales Hospital, Sydney, Australia
    J Natl Cancer Inst 96:683-96. 2004
    ..The basic region-leucine zipper protein c-Jun has been linked to cell proliferation, transformation, and apoptosis. However, a direct role for c-Jun in angiogenesis has not been shown...
  74. ncbi Improving anti-angiogenic therapy via selective delivery of cationic liposomes to tumour vasculature
    Crispin R Dass
    Johnson and Johnson Research, Box 4555, Strawberry Hills 2012, Australia
    Int J Pharm 267:1-12. 2003
    ..This review discusses the potential of delivering therapeutic nucleic acids to tumour vasculature using cationic liposomes, vehicles recently demonstrated to be selectively delivered to tumour vasculature...
  75. ncbi Cytotoxicity issues pertinent to lipoplex-mediated gene therapy in-vivo
    Crispin R Dass
    Johnson and Johnson Research, Eveleigh, New South Wales, Australia
    J Pharm Pharmacol 54:593-601. 2002
    ....
  76. ncbi Biochemical and biophysical characteristics of lipoplexes pertinent to solid tumour gene therapy
    Crispin R Dass
    Johnson and Johnson Research, 1 Central Avenue, Australian Technology Park, 1430, Eveleigh, Australia
    Int J Pharm 241:1-25. 2002
    ..Current research in this dynamic technological field is aimed at the development of cationic lipids that have negligible toxic effects and enhanced transfection capabilities...
  77. ncbi Vehicles for oligonucleotide delivery to tumours
    Crispin R Dass
    Johnson and Johnson Research, Strawberry Hills, Australia
    J Pharm Pharmacol 54:3-27. 2002
    ..A discourse on how the chemical and physical properties of these carriers may affect the uptake of ONs into cells, particularly in-vivo, forms a major basis of this review...
  78. ncbi Transcription factor Egr-1 supports FGF-dependent angiogenesis during neovascularization and tumor growth
    Roger G Fahmy
    Centre for Vascular Research, University of New South Wales, Sydney NSW 2052, Australia
    Nat Med 9:1026-32. 2003
    ..Egr-1 DNAzymes also repressed neovascularization of rat cornea. Thus, microvascular endothelial cell growth, neovascularization, tumor angiogenesis and tumor growth are processes that are critically dependent on Egr-1...
  79. ncbi Cyclodextrins and oligonucleotide delivery to solid tumours
    Crispin R Dass
    Genetic Technologies Pty Ltd, Hanover St 3065 Fitzroy Australia
    J Drug Target 12:1-9. 2004
    ..The physicochemical properties of these oligosaccharide molecules, and the barriers posed by the solid tumour itself, factors that affect may affect the uptake of oligonucleotides by CyDs, are the major foci of this review...
  80. ncbi A model for evaluating selective delivery of plasmid DNA to tumours via the vasculature
    Crispin R Dass
    School of Biomedical Sciences, Charles Sturt University, Wagga Wagga 2678, Australia
    Cancer Biother Radiopharm 17:501-5. 2002
    ..This tumour model has the potential of screening delivery vehicles as well as therapeutic agents for the capacity of selective delivery to tumours via the vasculature...
  81. ncbi Cellular uptake, distribution, and stability of 10-23 deoxyribozymes
    Crispin R Dass
    Johnson and Johnson Research Laboratories, Eveleigh, Australia
    Antisense Nucleic Acid Drug Dev 12:289-99. 2002
    ..The present study demonstrates that DNAzymes with a 3'-inversion are readily delivered into cultured cells and are functionally stable for several hours in serum and within cells...
  82. ncbi Brothers in arms: DNA enzymes, short interfering RNA, and the emerging wave of small-molecule nucleic acid-based gene-silencing strategies
    Ravinay Bhindi
    Centre for Vascular Research, The University of New South Wales, Sydney, NSW 2052, Australia
    Am J Pathol 171:1079-88. 2007
    ..This review tracks current movements in these technologies, focusing mainly on DNA enzymes and short interfering RNA, because these are poised to play an integral role in antigene therapies in the future...
  83. ncbi Liposome-mediated delivery of oligodeoxynucleotides in vivo
    Crispin R Dass
    DNAzyme Technology, Johnson and Johnson Research, Strawberry Hills, Australia
    Drug Deliv 9:169-80. 2002
    ..This result increases ODN uptake in target cells. Several liposomal formulations with proven potential for ODN delivery in vivo are discussed in this article...